|
KMID : 0981820100300060600
|
|
Korean Journal of Laboratory Medicine
2010 Volume.30 No. 6 p.600 ~ p.605
|
|
|
Clinical Relevance of Elevated Levels of Serum Soluble Interleukin-2 Receptor alpha (sIL-2Ra) in Patients with Non-Hodgkin’s Lymphoma
|
|
Jo Seon-A
Hwang Sang-Hyun
Chang Chul-Hun L.
Kim Shine-Young
Shin Ho-Jin
Chung Joo-Seop
Sol Mee-Young
Lee Eun-Yup
|
|
|
Abstract
|
|
|
|
Levels of soluble interleukin-2 receptor alpha (sIL-2Ra) are known to increase in the sera of patients with certain malignancies, including malignant lymphoma. This study aimed to assess the clinical significance of the sIL-2Ra level in non-Hodgkin’s lymphoma (NHL). We used ELISA to measure the sIL-2Ra levels in 48 newly diagnosed and untreated patients with NHL and evaluated the correlation between the sIL-2Ra levels and clinical characteristics and the International Prognostic Index (IPI). We monitored serum sIL-2Ra in 7 patients to compare the changes in their clinical progress with these levels. High levels of serum sIL-2Ra (≥2,000 U/mL) correlated well with parameters defining the high risk group according to the IPI, i.e., high tumor burden at diagnosis (stage III+IV) and lactate dehydrogenase ≥472 U/L. The levels were also associated with B symptoms, bone marrow involvement, and poor response to therapy. The sIL-2Ra level decreased during complete remission and was elevated during disease progression or relapse. A high level of sIL-2Ra was significantly associated with a low survival rate. These results suggest that serum sIL-2Ra might be useful as a biomarker for evaluating the prognosis of patients with NHL at the time of diagnosis and during therapy. A well-controlled, large-scale study is needed to clarify the clinical significance of sIL-2Ra in specific groups of NHL.
|
|
|
KEYWORD
|
|
|
Soluble interleukin-2 receptor (sIL-2R), International Prognostic Index, Non-Hodgkin’s lymphoma
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|